The turmoil in Ukraine could trigger a market correction, says Kenny Polcari. But don't let that scare you. Just pay attention.» Read More
Is alternative energy in your investing future?
Was the selloff in Citigroup shares overdone? The stock tanked 7 percent to a 4-year low--and lost more than than $16 billion in market value--after an analyst downgraded the nation's biggest bank, citing concerns about its capital needs.
Last month's gains -- 1.5 percent for the Standard & Poor's 500 and 5.8 percent for Nasdaq -- belie a trend of withering leadership, where a handful of technology shares are doing the heavy lifting while the rest of the market stalls or fades.
Historically November has been a better month for the markets than October, especially for the NASDAQ. As stocks finish on a positive note for the month of October, here is the historical performance for both months.
On Halloween, five-star fund manager Peter Klein sees some saints among the corporate hobgoblins. All of the Fifth Third Asset Management portfolio manager's stock selections have "issues," he concedes. But Klein sees fewer tricks and more treats ahead for these companies.
The World Wide Web has given a dramatic new meaning to the phrase "net profits." Just ask five-star fund manager Ryan Jacob, portfolio manager of Jacob Internet Fund. Read his five choices for an investor's Internet interests.
They're not the most exciting companies on the stock exchanges, and five-star trader Neil Hennessey says that may be just the point. The president and portfolio manager of Hennessy Funds offered up five overlooked stocks for CNBC's "5 For 5."
Even as much of the economy contracts, health care continues to grow, and investment opportunities continue to grow with it. What to choose among those investment opportunities? Analyst Michael Magiera of Manning & Napier looks past some of the more volatile pharmaceutical stocks.
Looking at the market, what does a big-market player see? Randall Eley, president and chief investment officer of the Edgar Lomax Co., and John Bollinger, president of Bollinger Capital Management, shared their insights -- and stock picks.
Steven Neimeth, portfolio manager of the SunAmerica Value Fund, sees plenty of positives in this turbulent market. The strategist offered CNBC his view of the economy -- and named the stocks he likes.
Norsk Hydro, one of Norway's largest companies, on Tuesday announced plans to withdraw its shares from the New York Stock Exchange as part of an effort to streamline and simplify operations and financial reporting.
Even with the major-indexes in a seeming free-fall, there are ways for investors to make money. Experts Monday spoke with CNBC to discuss some smart strategies to employ in a difficult market.
Many are quick to say that when it comes to investing little has changed since the crash. Twenty years later, however, Wall Street and the securities business are quite a bit different.
Sure they both happened in October and were case studies in fear and panic. The big difference is that investors lost their shirts in 1929, while in 1987 it was more like misplacing your wallet for about a year.
It's hard to believe but CNBC did not exist at the time., but CNBC veterans Bill Griffeth, Sue Herera and Ron Insana, then at FNN, covered the event. Here's how they remember it.
Top market theorists, economists, authors, money managers, Wall Street executives and a key Congressman share their thoughts on what happened and what's different today.
Mark Haines and I spoke with NYSE CEO John Thain this morning about the future of the NYSE floor, what the NYSE will be buying next, and other topics: Will the NYSE buy the NYMEX? I asked Diego Perfumo, who covers global exchanges for Equity Research.
Sprint Nextel shares fell almost 4 percent Tuesday a day after the No. 3 U.S. mobile-phone service warned it would not meet 2007 financial targets and said its chief executive had stepped down.
Scott Richter, portfolio manager with Fifth Third Asset Management, oversees the Fifth Third Disciplined Large Cap Value Fund. The fund is up 8 percent year-to-date and 13 percent over the last three years. The strategist offered CNBC viewers and CNBC.com readers a few of his favorite stocks in the health care and biotechnology sector.
Coming soon — well, maybe not that soon — to a theater near you: The story of a depraved, drug-addicted stock swindler. And the story is true.